Market Access News | pharmaphorum

News

NICE turns down Takeda colorectal cancer drug

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.

News

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in

News

FDA approval gives BMS an edge in NSCLC treatment

Bristol Myers Squibb (BMS) has secured

News

Gilead strikes deal to expand HIV drug access in 120 countri...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free

News

Revisionist history on healthcare at the VP debate

In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.

News

Blue Shield of California bypasses PBMs to slash Humira pric...

Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the price of Humira by up to 90%

NICE turns down Takeda colorectal cancer drug

Mounjaro and Zepbound shortages over, declares FDA

FDA approval gives BMS an edge in NSCLC treatment

Gilead strikes deal to expand HIV drug access in 120 countri...

Revisionist history on healthcare at the VP debate

Blue Shield of California bypasses PBMs to slash Humira pric...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks